Literature DB >> 9613951

Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma.

A L Jayewardene1, F Zhu, F T Aweeka, J G Gambertoglio.   

Abstract

Indinavir is a member of a class of protease inhibitors that actively prevent the acquired immunodeficiency syndrome virion from maturing. A high-performance liquid chromatographic (HPLC) assay was developed and validated for the determination of indinavir in human plasma. Indinavir and the internal standard were isolated from the plasma by ether extraction. The residue after evaporation of ether was reconstituted with buffer and injected onto a C4 reversed-phase column eluted isocratically with a mobile phase consisting of 35:65 (v/v) of acetonitrile and buffer. A wavelength of 210 nm was found to be optimum for detection. The calibration range of this assay was from 10 to 5000 ng/ml and coefficients of variation for the assay ranged from 4.6% to 11.0% for three different drug concentrations and the limit of quantitation was 10 ng/ml. During the validation, short-term stability of the drug in plasma, stability during heat deactivation and on repeated freezing and thawing of plasma was evaluated. The overall recovery of indinavir by the ether extraction method was 91.4%. This HPLC assay was found to be a simple and reproducible method for monitoring indinavir levels in human plasma obtained during clinical trials of the drug.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613951     DOI: 10.1016/s0378-4347(97)00607-5

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  7 in total

1.  Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.

Authors:  D Demarles; C Gillotin; S Bonaventure-Paci; I Vincent; S Fosse; A M Taburet
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.

Authors:  Caroline Solas; Isabelle Poizot-Martin; Marie-Pierre Drogoul; Isabelle Ravaux; Catherine Dhiver; Alain Lafeuillade; Thierry Allegre; Malika Mokhtari; Jacques Moreau; Gérard Lepeu; Nathalie Petit; Alain Durand; Bruno Lacarelle
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

3.  Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.

Authors:  Lauriane Goldwirt; Joséphine Braun; Nathalie de Castro; Isabelle Charreau; Aurélie Barrail-Tran; Constance Delaugerre; François Raffi; Caroline Lascoux-Combe; Jean-Pierre Aboulker; Anne-Marie Taburet; Jean-Michel Molina
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

4.  Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.

Authors:  Caroline Solas; Alain Lafeuillade; Philippe Halfon; Stéphane Chadapaud; Gilles Hittinger; Bruno Lacarelle
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

5.  Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.

Authors:  Caroline Solas; Nicolas Simon; Marie-Pierre Drogoul; Sylvie Quaranta; Véronique Frixon-Marin; Véronique Bourgarel-Rey; Corinne Brunet; Jean-Albert Gastaut; Alain Durand; Bruno Lacarelle; Isabelle Poizot-Martin
Journal:  Br J Clin Pharmacol       Date:  2007-05-22       Impact factor: 4.335

Review 6.  Nanotechnology: a focus on nanoparticles as a drug delivery system.

Authors:  Jeffrey D Kingsley; Huanyu Dou; Justin Morehead; Barrett Rabinow; Howard E Gendelman; Christopher J Destache
Journal:  J Neuroimmune Pharmacol       Date:  2006-09       Impact factor: 4.147

7.  Simple, Rapid and Validated LC Determination of Lopinavir in Rat Plasma and its Application in Pharmacokinetic Studies.

Authors:  Rahul Vats; Aditya Narasimha Murthy; Punna Rao Ravi
Journal:  Sci Pharm       Date:  2011-09-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.